- Resource Type:
- Presentation
AATS Expert Consensus: Treatment of High-Risk Non-Small Cell Lung Cancer
May 14, 2022
Elizabeth David , Invited Discussant , University of Colorado Anschutz Medical Center
Scott Swanson , Abstract Presenter , Brigham and Women's Hospital
102nd Annual Meeting, Boston, MA, USA
Hynes Convention Center, Room 312
Elizabeth David
Invited Discussant
Dr. David is an Associate Professor of Surgery in the Department of Surgery at the University of Colorado Anschutz Medical Campus. She is a thoracic surgeon in clinical practice with advanced training in thoracic oncology and a strong interest in clinical research. She completed a Masters of Advanced Study in Clinical Research. Her research interest lies in health services research focusing on oncologic outcomes and decision making for patients with advanced stage non-small cell lung cancer (NSCLC) treated with surgery. She is a committed surgical educator and has served as an associate program director for both integrated and traditional CT surgery training programs. Dr. David is committed to advancing science and patient care through clinical trials and has served as an institutional PI for several multicenter trials.
Scott Swanson
Abstract Presenter
Dr. Scott J. Swanson is a thoracic surgeon and director of Minimally Invasive Thoracic Surgery at Brigham and Women’s Hospital. He is associate chief of surgery at Dana-Farber/Brigham and Women’s Cancer Center and is a professor of surgery at Harvard Medical School.
Dr. Swanson received his medical degree from Harvard Medical School and completed his general and cardiothoracic surgical residencies at the Brigham. He completed a fellowship in vascular biology at Harvard Medical School and a thoracic oncology fellowship at the Brigham. Dr. Swanson is board certified in surgery and thoracic surgery. He has been listed as one of America’s Top Doctors by Castle Connolly and named a top thoracic surgeon by Boston Magazine.
Dr. Swanson’s clinical interests include minimally invasive thoracic surgery and lung cancer. His research is focused on better understanding early stage lung cancer, its biologic fingerprint and clinical behavior.